Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1995-12-21
1998-12-29
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241401, 53038729, 5303893, A61K 39395, C07K 1636
Patent
active
058537228
ABSTRACT:
The use of anti-C5 antibodies to reduce the dysfunction of the immune and hemostatic systems associated with extracorporeal circulation procedures, such as, cardiopulmonary bypass procedures, is disclosed. The antibodies have been found to significantly reduce complement activation, platelet activation, leukocyte activation, and platelet-leukocyte adhesion associated with such procedures.
REFERENCES:
patent: 4686100 (1987-08-01), Raffin et al.
patent: 5135916 (1992-08-01), Sims et al.
patent: 5506247 (1996-04-01), Sindelar et al.
Harris et al. Tib Tech 11:42-45 (1993).
Wurzner et al. Complemt. inflamm 8:328-340 (1981).
Mollnes Ann Thorac Surg 52:92-7 (1991).
Bator et al. Mediators of Inflammation 2:135-141 (1993).
Videm et al. J. Thorac Cardiovasc Surg 101:654-60 (1991).
Altieri, et al., "Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: An alternative intiation of the coagulation protease cascade" Proc Natl Acad Sci USA 85:7462-7466, 1988.
Arnaout, et al. "Increased Expression of an Adhesion-Promotion Surface Glycoprotein in the Granulocytopenia of Hemodialysis" N Engl J Med 312:457-462, 1985.
Arnaout, "Structure and Function of the Leukocyte Adhesion Molecules CD11/CD18" Blood 75:1037-1050, 1990.
Aslan, et al., "The factors effecting complement activation in open heart surgery" J Cardiovasc Surg 33:754-760, 1992.
Bidstrup, et al., "Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (TrasyL0L)" J Thorac Cardiovasc Surg 973:364-372, 1989.
L. Casey, "Role of Cytokines in the Pathogenesis of Cardiopulmonary-Induced Multisystem Organ Failure" Ann Thorac Surg 56:S92-6, 1993.
Cavarocchi, et al., "Complement activation during cardiopulmonary bypass" J Thorac Cardiovasc Surg91:252-258, 1986.
Cavarocchi, et al., "Oxygen free radical generation during cardiopulmonary bypass: correlation with complement activation" Circulation74 (suppl III) :130-133, 1986.
Chenoweth, et al., "Complement Activation during Cardiopulmonary Bypass" N Eng J Med304:497-502 1981.
D. Chenoweth, "Anaphylatoxin Formation in Extracorporeal Circuits" Complement3:152-165, 1986.
Chiu, et al., "Complement (C3, C4) Consumption in Cadiopulmonary Bypass, Cardioplegia, and Protamine Administration" Ann Thorac Surg37:229-232, 1984.
Copeland, et al., "Bleeding and Anticoagulation" Ann Thorac Surg47:88-95, 1989.
Cosgrove, et al., "Aprotinin Therapy for Reoperative Myocardial Revascularization: A Placebo-Controlled Study" Ann Thorac Surg54:1031-38, 1992.
Dreyer, et al., "Neutrophil Accumulation in Ischemic Canine Myocardium: Insights into Time Course, Distribution, and Mechanism of Localization During Early Reperfusion" Circ84:400-411, 1991.
Finn, et al., "Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass" J Thorac Cardiovasc Surg, 105:234-241, 1993.
Furie, et al., "E-Selectin (Endothelial-Leukocyte Adhesion Molecule-1) Is Not Required for the Migration of Neutrophils across IL--1--Stimulated Endothelium in Vitro" J Immunol148:2395-2404, 1992.
Gillinov, et al., "Complement Inhibition With Soluble Complement Receptor Type 1 in Cardiopulmonary Bypass" Ann Thorac Surg55:619-624, 1993.
Gillinov, et al., "Neutrophil Adhesion Molecule Expression During Cardiopulmonary Bypass with Bubble and Membrane Oxygenators" Ann Thorac Surg56:847-853, 1993.
Gillinov, et al., "Complement and Neutrophil Activation During Cardiopulmonary Bypass: A Study in the Complement--Deficient Dog" Ann Thorac Surg57:345-352, 1994.
Hackmann, et al. "A Trial of Desmopressin (1--Desamino--8--D--Arginine Vasopressin) to Reduce Blood Loss in Uncomplicated Cardiac Surgery" N Engl J Med321:1437-1442, 1989.
Haslam, et al., "Complement activation during cardiopulmonary bypass" Anaesthesia, 35:22-26, 1980.
Jones, et al. "Cardiopulmonary bypass and complement activation" Anaesthesia, 37:629-633, 1982.
Kirklin, et al., "Complement and the damaging effects of cardiopulmonary bypass" J Thorac Cardiovasc Surg86:845-857, 1983.
Levy et al., "Inflammation and cardiopulmonary bypass" Can J Anaesth40:1009-1015, 1993.
Miyamoto, et al. "Analysis of Complement Activation Profile during Cardiopulmonary Bypass and Its Inhibition by FUT-175" ASAIO J31:508-511, 1985.
Moat, et al. "Complement inhibition may attenuate acute lung injury after cardiopulmonary bypass in pigs" Am Rev Respir Dis145:A845, 1992.
Moat, et al., "Humoral and Cellular Activation in a Simulated Extracorporeal Circuit" Ann Thorac Surg56:1509-1514, 1993.
Mohr, et al., "The hemostatic effect of transfusing fresh whole blood versus platelet concentrates after cardiac operations" J. Thorac. Cardiovasc. Surg.96:530-534, 1988.
Mollnes, et al., "Identification of a Human C5 .beta.--Chain Epitope Exposed in the Native Complement Component but Concealed in the SC5b-9 Complex" Scand. J. Immunol.28:307-312, 1988.
Moongkarndi, et al., "Monoclonal antibodies against the fifth component of human complement" Immunobiol.162:397, 1982.
Moongkarndi, et al., "Immunological and functional properties of two monoclonal antibodies against human C5"0 Immunobiol.165:323, 1983.
Montz, et al., "Regulation of the Human Autologous T Cell Proliferation by Endogenously Generated C5a" Cellular Immunol.127:337-351, 1990.
Nathan, et al., "Cytokine-induced Respiratory Bur Human Neutrophils: Dependence on Extracellular Matrix Proteins and CD11/CD18 Integrins" J Cell Biol109:1341-1349, 1989.
Nilsson, et al., "Heparin-Coated Equipment Reduces Complement Activation during Cardiopulmonary Bypass in the Pig" Artif Organs14:46-48, 1990.
.O slashed.vrum, et al., "Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations" J Thorac Cardiovasc Surg,105:78-83, 1993.
Palabrica, et al., "Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P--selectin on adherent platelets" Nature359:848-851, 1992.
Parker, et al., "Changes in serum complement and immunoglobulins following cardiopulmonary bypass" Surgery71:824-827, 1972.
Rinder, et al., "Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion" Transfusion,31:409-414, 1991.
Rinder, et al, "Cardiopulmonary Bypass Induces Leukocyte-Platelet Adhesion" Blood,79:1201-1205, 1992.
Rocha, et al., "Does despmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?" Circulation77:1319-1323, 1988.
Seghaye, et al., "Complement activation during cardiopulmonary bypass in infants and children" J Thorac Cardiovasc Surg106:978-987, 1993.
Steinberg, et al., "Cytokine and complement levels in patients undergoing cardiopulmonary bypass" J Thorac Cardiovasc Surg106:1008-1016, 1993.
Simpson, et al., "Reduction of Experimental Canine Myocardial Reperfusion Injury by a Monoclonal Antibody (Anti-Mo1, Anti-CD11b) That Inhibits Leukocyte Adhesion" J Clin Invest81:624-629, 1988.
Sonntag and Stein, "Arteriopathic complications during treatment of subarachnoid hemorrhage with epsilonaminocaproic acid" J Neurosurg40:480-484, 1974.
Stanuton, et al., "Primary Structure of ICAM-1 Demonstrates Interaction between Members of the Immunoglobulin and Integrin Supergene Families" Cell52:925-933, 1988.
Staunton, et al., "Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1" Nature339:61-64, 1989.
Taggart, et al., "Endotoxemia, Complement, and White Blood Cell Activation in Cardiac Surgery: A Randomized Trial of Laxatives and Pulsatile Perfusion" Ann Thorac Surg57:376-382, 1984.
Tulunay, et al., "Complement (C3, C4) and C--reactive Protein Responses to Cardiopulmonary Bypass and Protamine Administration" Anaesth Intens Care21:50-55, 1993.
Videm, et al., "Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro" J. Thorac. Cardiovasc. Surg.,97:764-770, 1989.
Videm, et al., "Complement Activation woth Bubble and Membrane Oxygenators in Aortocoronary Bypass Grafting" Ann Thorac Surg50:387-731, 1990.
Videm, et al., "Time for New Concepts About Measurement of C
Rollins Scott
Smith Brian R.
Squinto Stephen P.
Alexion Pharmaceuticals, Inc.
Feisee Lila
Fidel Seth A.
Gambel Phillip
Klee Maurice M.
LandOfFree
Use of C5-specific antibodies for reducing immune and hemostatic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of C5-specific antibodies for reducing immune and hemostatic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of C5-specific antibodies for reducing immune and hemostatic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1421483